. Correlation between change of CTC number (baseline and after 6-12 weeks of treatment) and clinical outcome in mCRC patients treated with chemotherapy-bevacizumab (A) and chemotherapy-cetuximab (B) In a group of 20 patients treated with cetuximab, the median number of baseline CTC was 2.6 (range 2-11). After 6-12 weeks of treatment, CTC count dropped to 0 in 3/20 (15%) patients; to 1 or 2 in 11/20 patients (55%) and in 6/20 patients (30%) remained persistently high ( ‡3). After 12 weeks of treatment, 6/6 (100%) patients with persistently high CTC count were found in PD, whereas 13/14 (93%) patients with decreased number of CTC were found with stable disease or partial response (Table 1, B) .
Similar to what observed in breast cancer, we suppose that the lack of predictive value of CTC in mCRC may depend on the use of bevacizumab.
We hypothesize that bevacizumab may alter CTC biological features, thus preventing CellSearch from capturing them. Indeed, it is well recognized that bevacizumab, through the inhibition of tumor angiogenesis, leads to intratumoral hypoxia [2] , which is a crucial trigger of tumor progression, invasive cell behavior and epithelial mesenchymal transition (EMT) [3] . Some provocative studies have also reported that vascular endothelial growth factor inhibitors, although efficient to reduce primary tumor growth, may promote tumor metastasis [4] .
Thus, bevacizumab-induced hypoxia may generate in the primary tumor a selected population of cells undergoing EMT, which loose cell-cell contact, become motile and acquire mesenchymal features. During this process, epithelial markers as EpCam and cytokeratins are often down-regulated, making these cells undetectable by CellSearch system. Thus, the meaning of '0 CTC' in our patients with progression of disease may be simply due to underestimation of CTC by CellSearch.
Recently, Mego et al. [5] for the first time used the term 'undetectable CTC' instead of 'negative CTC' in breast cancer patients, suggesting that this status may be due to underestimation by CellSearch of CTC, which undergone EMT.
Our results are in agreement with those from Tol et al. [6] who have reported that 80% of patients with mCRC with PD on computed tomography scan imaging have low CTC count at 1-2 weeks and concluded that CTC counts alone cannot accurately predict the clinical outcome.
We believe that the lack of predictive value of CTC count in mCRC patients treated with bevacizumab may represent the first example of drug-related 'undetectable CTC status' and suggest caution when using CellSearch to evaluate CTC count as predictive factor for patients with mCRC receiving bevacizumab. 
